This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crook, T. R. Articles by McLean, A. E. M. Search for Related Content PubMed PubMed Citation Articles by Crook, T. R. Articles by McLean, A. E. M.

Cytotoxicity, DNA Cross-Linking, and Single Strand Breaks Induced by Activated Cyclophosphamide and Acrolein in Human Leukemia Cells

Toxicology Laboratory, School of Medicine, University College London, London, WC1 6JF [T. R. C., A. E. M. M.], and Department of Radiotherapy and Oncology, University College Hospital, Gower Street, London WC1 [R. L. S.], England

The in vitro cytotoxicity and mechanism of action of cyclophosphamide (CP) were studied in a dual cell culture system, using rat hepatocytes and K562 human chronic myeloid leukemia cells. Cytotoxicity and DNA damage were measurable in K562 cells using CP concentrations that are clinically attainable. Alkaline elution analysis of cellular DNA demonstrated the presence of concentration- and time-dependent DNA inter-strand cross-links, DNA-protein cross-links, and DNA single strand breaks in K562 cells following a 1-h exposure to cyclophosphamide activated by hepatocytes.

Hepatocyte-activated CP was 3 to 4 times more potent than phosphoramide mustard with regard to cytotoxicity and induction of DNA interstrand cross-links. Exposure to phosphoramide mustard did not produce single strand breaks, but exposure of K562 cells to acrolein resulted in substantial levels of single strand breaks. The demonstration of acrolein-induced single strand breaks following exposure to activated CP is a novel finding and suggests that acrolein may have a role in the cytotoxicity of CP.

¹ Recipient of support from the Trustees of the Wagner Foundation and the Special Trustees of University College Hospital for funding a studentship.

² To whom requests for reprints should be addressed.

Received 2/12/86. Revised 6/10/86. Accepted 6/12/86.

This article has been cited by other articles:

				S.-i. Kim, G. P. Pfeifer, and A. Besaratinia Lack of Mutagenicity of Acrolein-Induced DNA Adducts in Mouse and Human Cells Cancer Res., December 15, 2007; 67(24): 11640 - 11647. [Abstract] [Full Text] [PDF]

				N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials Blood, May 1, 2007; 109(9): 3936 - 3944. [Abstract] [Full Text] [PDF]

				A. Aguilar-Mahecha, B. F. Hales, and B. Robaire Chronic Cyclophosphamide Treatment Alters the Expression of Stress Response Genes in Rat Male Germ Cells Biol Reprod, April 1, 2002; 66(4): 1024 - 1032. [Abstract] [Full Text] [PDF]

				J. M. Hartley, V. J. Spanswick, M. Gander, G. Giacomini, J. Whelan, R. L. Souhami, and J. A. Hartley Measurement of DNA Cross-linking in Patients on Ifosfamide Therapy Using the Single Cell Gel Electrophoresis (Comet) Assay Clin. Cancer Res., March 1, 1999; 5(3): 507 - 512. [Abstract] [Full Text] [PDF]